Janssen submits application to EMA for the use of daratumumab in newly diagnosed myeloma patients

Janssen has submitted an application to the European Medicines Agency (EMA) to extend the marketing authorisation for daratumumab (Darzalex┬«) to include its use in combination with bortezomib (Velcade┬«), melphalan and prednisone as a treatment for newly diagnosed myeloma patients who are ineligible for an autologous stem cell transplant (ASCT). This decision is based on the…

Details